News & Trends - Biotechnology

Biotech companies and investment risk – new study

Health Industry Hub | January 13, 2021 |
[Total: 1    Average: 4/5]

Biotech News: Contrary to public perception, investing in biotech companies may not entail higher risk than investing in non-biotech companies, according to a new report.

Researchers studied the financial performance of 319 biotechnology companies focused on developing therapeutic products that completed Initial public offerings (IPOs) from 1997-2016.

When it came to companies that eventually had their stocks delisted, there was no statistically significant difference between biotech companies and firms in the control group. In both cases, the most common reason for delisting was a merger or an acquisition.

With respect to acquisitions, more biotech companies with a market capitalisation of greater than $1 billion were acquired compared to non-biotech companies.

According to the study, bankruptcy or liquidation was not common in either group (3.1% for biotech and 2.5% for control). There was also no difference between groups for the interval between IPO and delisting. Overall, this indicates that biotech and control companies had similar rates of success and failures.

“Despite the extraordinary performance of the biotech sector in recent years, biotech is still often portrayed as a high-risk investment. Our study suggests that, in fact, the high-risk, high-return pattern associated with biotech companies after their IPO is a common characteristic of companies completing IPOs from other sectors as well,” said Dr. Fred Ledley, Director of the Centre for Integration of Science and Industry “This study also suggests that, for these emerging, public companies, the science-based, biotech business model generates equivalent economic value to more traditional, revenue-based business models.”

The authors noted that caution should be used in interpreting these findings, as most biotech companies with products in development were acquired before the end of the study period and most revenue from these products would not have been accrued until after acquisition. Thus, the revenues were not recognised in their analysis.

According to the study, a measure of company success in the biotechnology sector is less likely to be based on sustained revenues or profits, but rather acquisition.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Sustained COVID-19 impact on cancer services and procedures

Sustained COVID-19 impact on cancer services and procedures

Health Industry Hub | January 15, 2021 |

MedTech News: Cancer Australia has released the latest in a series of reports analysing for the first time the significance […]

More


News & Trends - Medical Technology

MedTech News - Healthscope hospital leading in high-tech medical surgery

Healthscope hospital leading in high-tech medical surgery

Health Industry Hub | January 15, 2021 |

MedTech News: Healthscope’s Knox Private Hospital recently celebrated two key milestones, underscoring its reputation as a leading proponent of high-tech […]

More


News & Trends - Pharmaceuticals

Pharma News - Experts comment on AstraZeneca vaccine efficacy concerns

Experts comment on AstraZeneca vaccine efficacy concerns

Health Industry Hub | January 15, 2021 |

Pharma News: In light of the comments made regarding AstraZeneca’s COVID-19 vaccine efficacy by the Australian and New Zealand Society […]

More


Communication

Communication Pharma Biotech Medtech - Secrets of persuasion to influence anyone

Secrets of persuasion to influence anyone

Health Industry Hub | January 15, 2021 |

To understand the art of persuasion, you can turn to cognitive science for guidance in dealing with the unconscious mind. […]

More